Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.

European journal of clinical investigation - 1 Sept 2021

Rassy Elie, Boussios Stergios, Pavlidis Nicholas

Abstract excerpt

BACKGROUND: Cancers of unknown primary (CUP) are highly aggressive tumours with limited molecular characterization. These tumours can be particularly sensitive to immune checkpoint inhibitors (ICI) by mounting a seemingly more effective anti-tumour immune response. Unlike other tumour lineages, the biological basis and clinical efficacy of ICI in CUP remain largely unknown. MATERIALS AND METHODS: The cBioPortal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Neoplasms, Unknown Primary

Share to Oncogenes

Share to Proto-Oncogene Proteins p21(ras)

Share to PTEN Phosphohydrolase

Share to Survival Rate

Source

Identifiers

PMID: 33970501
DOI: 10.1111/eci.13583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.PMID 33970501Read ↗

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.Semantic proximity Read ↗

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.Semantic proximity Read ↗

Genetic characterisation of molecular targets in carcinoma of unknown primary.Semantic proximity Read ↗

Molecular driver alterations and their clinical relevance in cancer of unknown primary site.Semantic proximity Read ↗

Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.Semantic proximity Read ↗

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.Semantic proximity Read ↗

Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.Semantic proximity Read ↗

Exploring the molecular landscape of cancer of unknown primary: A comparative analysis with other metastatic cancers.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.Semantic proximity Read ↗

Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.Semantic proximity Read ↗

Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).Semantic proximity Read ↗

Genomic Alterations and Possible Druggable Mutations in Carcinoma of Unknown Primary (CUP)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.